Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-04-24 22:30 |
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alem…
|
English | 101.9 KB | ||
| 2023-04-24 22:30 |
Cellectis implémente CLLS52 pour la première fois en clinique avec l’alemtuzuma…
|
French | 66.0 KB | ||
| 2023-04-17 08:00 |
Réunion annuelle de l’American Association for Cancer Research (AACR) : Cellect…
|
French | 80.7 KB | ||
| 2023-04-17 08:00 |
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhanc…
|
English | 69.4 KB | ||
| 2023-04-12 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 87.7 KB | ||
| 2023-04-12 22:30 |
Monthly information on share capital and company voting rights
|
English | 80.3 KB | ||
| 2023-04-11 22:30 |
Cellectis annonce le dosage de son premier patient en Europe avec le produit ca…
|
French | 71.4 KB | ||
| 2023-04-11 22:30 |
Cellectis Announces Dosing of the First Patient in Europe with its In-house Man…
|
English | 64.7 KB | ||
| 2023-04-04 22:30 |
Cellectis a conclu le contrat de souscription de bons de souscription d’actions…
|
French | 71.7 KB | ||
| 2023-04-04 22:30 |
Cellectis enters into warrant agreement with the European Investment Bank relat…
|
English | 91.1 KB | ||
| 2023-03-15 22:02 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 83.5 KB | ||
| 2023-03-15 22:02 |
Monthly information on share capital and company voting rights
|
English | 76.2 KB | ||
| 2023-03-14 22:00 |
Cellectis présentera un poster sur les cellules CAR T MUC1 éditées par TALEN® c…
|
French | 131.3 KB | ||
| 2023-03-14 22:00 |
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targe…
|
English | 105.2 KB | ||
| 2023-03-08 22:45 |
Cellectis publie ses résultats financiers du quatrième trimestre 2022 et de l’e…
|
French | 464.8 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
